Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: potential treatment + lupus patients + medimmune  Related to the article below (Last Update: 5/12/2008)

AVI BioPharma Publishes Preclinical Data Reducing Inflammation in ...
CNNMoney.com -
TNF-mediated inflammatory diseases include a group of autoimmune disorders such as Crohn's disease, ulcerative colitis, systemic lupus erythematosus, ...AVII

eFluxMedia
Genentech and Biogen Idec Announce Top-Line Results from Phase II ...
PR-Inside.com (Pressemitteilung), Austria - Apr 29, 2008
The course of disease in SLE is highly variable among patients and like other autoimmune diseases, most lupus patients experience periods of illness called ...
Statement From the Lupus Foundation of America Regarding the ... Earthtimes (press release)
Genentech shares slide as Rituxan fails as lupus treatment Pharma Times (subscription)
Genentech, Biogen shares drop on drug news MarketWatch
San Francisco Chronicle
all 165 news articles »  DNA - BIIB
La Jolla Pharmaceutical Announces Positive 12-Month Interim ...
FOXBusiness - Apr 23, 2008
The Phase 3 study is designed to assess the ability of Riquent treatment to prevent or delay the time to renal flare in lupus patients with a history of ...LJPC
Interim Results from Boceprevir Phase II Study in Genotype 1 ...
FOXBusiness - Apr 27, 2008
The ongoing study evaluates boceprevir in 28-week and 48-week treatment regimens. In a 28-week treatment regimen in which patients received 4 weeks of ...
Three Studies Presented at 43rd EASL Showed Higher SVR for PEGASYS ... PR-CANADA.net (press release)
Final Results of Ideal Study Presented at Annual Meeting of the ... FOXBusiness
all 45 news articles »  SGP - SGP-B
Launches of at Least 15 New Biologic Therapies by 2017 Will Expand ...
PharmaLive.com (press release), PA -
"New biologic immunomodulatory agents will enter the market as late-line treatment options for indications with marketed TNF-alpha inhibitors such as ...
A week in Seattle's life sciences land
Seattle Post Intelligencer - May 5, 2008
Genentech said its Rituxan treatment failed to meet the company's goals in a study looking at Rituxan's potential use in patients with lupus. ...
Etanercept May Provide Benefit for Patients With Juvenile ...
DG News - May 9, 2008
There were no reported cases of tuberculosis, lupus; malignancies, lymphomas, nervous system disorders, or deaths. Among patients who received 8 years of ...
La Jolla Pharmaceutical Company Reports First Quarter Financial ...
WELT ONLINE, Germany - May 1, 2008
Lupus renal disease is a leading cause of sickness and death in patients with lupus. The Company has also developed potential small molecule drug candidates ...LJPC
A Clinical Electrophysiological Study of Emotional Lability in ...
Journal of Neuropsychiatry (subscription) - May 1, 2008
Analyses aimed to investigate possible associations between emotional lability in systemic lupus erythematosus patients and event-related potential markers ...
Sign of the wolf
Malaysia Star, Malaysia - Apr 26, 2008
Because of the variety of symptoms and organ system involvement with lupus patients, the severity of the disease in individual patients must be assessed in ...
Source: Google News

Pilot Clinical Trial of Dehydroepiandrosterone (DHEA) Versus Placebo for Sj?gren?s Syndrome -
SR PILLEMER, MT BRENNAN, V SANKAR, RA LEAKAN, JA … - Arthritis & Rheumatism (Arthritis Care & Research), 2004 - doi.wiley.com
... The trial therefore provided no evidence of potential efficacy. ... Treatment of systemic
lupus erythematosus with dehydroepiandrosterone: 50 patients ...

… , detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus -
DM Friedman, A Rupel, JP Buyon - Current Rheumatology Reports, 2007 - Springer
... condition must be weighed against potential toxicity of ... Treatment of the mother with
intravenous immunoglobulin (IVIG ... Heart Block in Neonatal Lupus Friedman et ...

New Prospects for Autoimmune Disease Therapy: B Cells on Deathwatch -
EWS CLAIR, TF TEDDER - Arthritis and rheumatism, 2006 - doi.wiley.com
... RA, Sj?gren?s syndrome, and systemic lupus erythema- tosus ... Lymphostat-B) as a possible
treatment for RA ... is needed to understand the potential benefits and ...

The Challenge of Analyzing the Proteome in Humans with Autoimmune Diseases -
SM CHAN, PJ UTZ - Annals of the New York Academy of Sciences, 2005 - Blackwell Synergy
... mice.16 This study highlights the potential use of ... lowering class of drugs (statins),
and treatment with a ... responses do not yet exist for lupus or rheumatoid ...

10th Anniversary Inflammation and Immune Diseases Drug Discovery and Development Summit -
M Braddock, C Murray - Expert Opin. Investig. Drugs, 2006 - Expert Opinion
... ?, IL-4 and TNF-a in systemic lupus erythematosus (SLE ... programme of anti-CD20 monoclonal
antibodies for the potential intravenous treatment of non ...

Phototherapy treatment of psoriasis today -
M Zanolli - Journal of the American Academy of Dermatology, 2003 - Elsevier
... was treating cutaneous mycobacterial infection on the face (lupus vulgaris ... Photodynamic
therapy for the treatment of psoriasis is a potential area of ...

Annual Update 2004/2005-Treatment of Musculoskeletal Disorders -
JR Prous - Drugs of the Future, 2005 - journals.prous.com
... Treatment of Musculoskeletal Disorders by Source. ... La Jolla Pharmaceutical, Systemic
lupus erythematosus, Abetimus sodium 2, ... MedImmune, Rheumatoid arthritis, MEDI- ...

Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications -
SA Greenberg - Neurology, 2007 - AAN Enterprises
... myeloid DC function for treatment of autoimmune ... stress response in autoimmune myositis:
potential role in ... Patients with systemic lupus erythematosus (SLE) have ...

Toll-like receptors and innate immune responses in systemic lupus erythematosus -
R Lafyatis, A Marshak-Rothstein - Arthritis Research & Therapy, 2007 - arthritis-research.com
... provide additional insight into the potential therapeutic role ... the IFN-signature
in lupus patients by microarray ... under active investigation for treatment of SLE ...

[PDF] Pilot Clinical Trial of Intravenous Doxycycline Versus Placebo for Rheumatoid Arthritis -
S PILLEMER, P GULKO, S LIGIER, C YARBORO, M … - J Rheumatol, 2003 - nslij-genetics.org
... of IV doxycycline as a treatment for RA ... of IV doxycycline would outweigh potential
disadvantages of IV ... spondy- loarthropathy, systemic lupus erythematosus, or ...
-

Source: Google Scholar

MedImmune Advances Potential Treatment For Patients With Lupus
MedImmune, Inc. today announced that it has begun dosing patients in a multi-dose, Phase 1b clinical trial with its monoclonal antibody (MAb) targeting interferon-alpha, known as MEDI-545. The study is designed to evaluate the safety and tolerability of multiple doses of the MAb in patients with systemic lupus erythematosus (SLE or lupus). The trial is the third clinical study underway with the antibody, which is also being evaluated in a single-dose Phase 1 trial in lupus patients and a Phase 1 study in patients with psoriasis.

"This multi-dose study marks an important milestone in MedImmune's efforts to develop innovative treatments for inflammatory diseases such as lupus," said Barbara White, vice president, clinical development, inflammatory disease. "Our therapeutic approach to addressing this area of high unmet medical need is supported by increasing evidence of type-1 interferon involvement in the pathology of immune system disorders, and we are pleased to extend clinical evaluation of our anti-interferon-alpha MAb to a second Phase 1 study in this patient population."
The Phase 1b trial will build on preliminary data from the ongoing Phase 1 study in lupus patients, as described in a presentation at the 8th International Lupus Consortium held May 24-26, 2007 in Shanghai. Early results from the single-dose trial show an acceptable safety profile and tolerability of MEDI-545.

In addition to advancing MEDI-545 as a potential treatment for lupus, with two Phase 1 trials underway, MedImmune has recently expanded the anti-interferon-alpha program to include other potential disease areas. The company initiated a Phase 1 trial in patients with psoriasis earlier in 2007 and plans to begin a trial in idiopathic inflammatory myopathies later this year.

About Anti-Interferon-Alpha MAb

MEDI-545 is a fully human MAb targeting interferon-alpha. Published data indicate that levels of interferon-alpha are elevated in many patients with active SLE and other autoimmune disorders, and may be associated with disease activity. Preclinical data from animal models suggest that MEDI-545 may suppress the abnormal immune activity associated with lupus by binding to the pattern of multiple interferon-alpha subtypes seen in the serum of lupus patients.

About Lupus

Approximately 350,000 individuals in the United States are affected with lupus, a chronic inflammatory disease that causes the body to attack its own tissues and organs, including the skin, joints, blood and kidneys. Treatments for lupus include anti-inflammatory drugs, antimalarials, corticosteroids and drugs approved for other purposes, such as immunosuppressive agents given to cancer patients undergoing chemotherapy or medicines developed to treat arthritis patients. Lupus occurs about 10 times more frequently in adult females than adult males, and is two to three times more common among African Americans, Hispanics, Asians and Native Americans.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 3,000 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com.

MedImmune, Inc.
http://www.medimmune.com
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.